{
    "eid": "2-s2.0-85140877954",
    "title": "Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment",
    "cover-date": "2022-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "cancer",
        "ChAdOx1",
        "COVID-19 vaccine",
        "immunogenicity",
        "Omicron",
        "SARS-CoV-2"
    ],
    "authors": [
        "Passakorn Wanchaijiraboon",
        "Nattaya Teeyapun",
        "Nussara Pakvisal",
        "Panot Sainamthip",
        "Thiti Susiriwatananont",
        "Nicha Zungsontiporn",
        "Nungruthai Suntronwong",
        "Preeyaporn Vichaiwattana",
        "Worata Klinsawat",
        "Nasamon Wanlapakorn",
        "Suebpong Tanasanvimon",
        "Virote Sriuranpong",
        "Yong Poovorawan",
        "Sutima Luangdilok"
    ],
    "citedby-count": 2,
    "ref-count": 25,
    "ref-list": [
        "Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer",
        "SARS-CoV-2 Infection in Cancer Patients: Effects on Disease Outcomes and Patient Prognosis",
        "High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study",
        "Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study",
        "Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients",
        "Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection",
        "Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients with Cancer Undergoing Treatment or Who Received a Stem Cell Transplant",
        "Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer",
        "Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment",
        "High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers",
        "Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study",
        "Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: A prospective cohort study",
        "Spike-antibody waning after second dose of BNT162b2 or ChAdOx1",
        "Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study",
        "mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: A prospective, multicentre, non-inferiority trial",
        "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine",
        "Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons",
        "Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers",
        "Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: A substudy of two randomised controlled trials (COV001 and COV002)",
        "Extended interval BNT162b2 vaccination enhances peak antibody generation",
        "Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60103476",
            "affilname": "King Mongkuts University of Technology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60103476",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chanthaburi",
            "@id": "112453702",
            "affilname": "Phrapokklao Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112453702",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "KCMH",
        "Medical Oncology Research Fund",
        "Phrapokklao Hospital Donation Fund",
        "Ratchadapiseksompotch Fund",
        "Sirivadhanabhakdi Foundation",
        "King Chulalongkorn Memorial Hospital",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}